ArticleEcancermedicalscience2025
Molecular characterisation of KRAS mutations in non-small cell lung cancer across all stages.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinicopathological Characteristics and Prognostic Impact of KRAS Mutations in Non-Small Cell Lung Cancer.Medicina (Kaunas, Lithuania) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Kirsten rat sarcoma virus (KRAS) mutations (KRASms) are detected in approximately 25% of non-small cell lung cancer (NSCLC) patients with adenocarcinoma. Next-generation sequencing (NGS) has enabled the identification of diverse KRASm subtypes with distinct prognoses, co-mutation patterns and clinical characteristics. This study aimed to investigate the clinical and pathological characteristics of KRASm patients across all stages of NSCLC. Methods: We analysed NSCLC patients from 2019 to 2021 using the Illumina Focus 52-gene targeted NGS panel, which detects DNA and RNA alterations. PD-L1 expression was assessed using the SP263 antibody. We examined the clinical and pathological characteristics of KRASm patients, including KRASm subtypes and co-mutations. Results: Of the 123 patients, 62 (50.4%) had KRASm, with a median age of 67 years (range 49-92). Of these, 79% were male, 87.1% had adenocarcinomas and only 8.1% were non-smokers. NGS alone was sufficient for molecular characterisation in 19.4% of cases; in 75.8%, an additional single molecular test was required. KRASm subtypes were distributed as follows: G12C (33.8%), G12V (25.8%), G12D (21%) and Q61H (6.5%). G12V was more prevalent in non-smokers (60%). Co-mutations were detected in 24.2% of patients, with PIK3CA being the most frequent. PD-L1 expression >50% was observed in 19.4% of patients. No significant associations were identified between KRAS subtypes and PD-L1 expression levels or co-mutations.Significant differences in the clinical stage were noted across KRASm subtypes. Early-stage disease accounted for 24.19% of KRASm cases, with G12D observed in 40% of these patients. However, G12C and G12V subtypes were more frequently associated with metastatic disease ( Conclusion: This study underscores the importance of assessing KRAS status and subtypes in NSCLC, particularly in early-stage disease, due to their association with metastatic risk. This could have relevance in treatment strategies and subsequent monitoring, which could necessarily be closer in higher risk patients. Moreover, while PD-L1 status shows potential as a prognostic factor in KRASm patients, further research is needed to confirm this relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.